Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages

  Flynn, Ann D ^a   Azar, Jose M ^b   Chiorean, Michael V ^a  

^a INDIANA UNIVERSITY   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; INFLIXIMAB; MESALAZINE; PREDNISONE; RITUXIMAB; ADALIMUMAB; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; PROTEIN BCL 2; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ADULT; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; COLONOSCOPY; CROHN DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PATIENT REFERRAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY; BIOPSY; CANCER RECURRENCE; COLONIC LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE INCREASE; ENDOSCOPIC BIOPSY; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HYBRIDIZATION; ILEOSTOMY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOMA; PROCTOCOLECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; SIGMOID; WHOLE BODY PET;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZATHIOPRINE; COLONIC NEOPLASMS; COLONOSCOPY; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROCTOCOLECTOMY, RESTORATIVE; REMISSION INDUCTION; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84876361204     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31827fec81     Document Type: Letter

References (8)

1. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
2. Cassaday RD, Malik JT, Chang JE. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011;11:289-292.
3. Mo N, Murthu S, O'Sullivan M. Regression of lymphoma after withdrawal of infliximab alone in an infliximab/methotrexate-treated RA patient. Rheumatology. 2011;50:808-810.
4. Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis. 2005;64:1098-1099.
5. Komatsuda A, Wakui H, Nimura T, et al. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008;18:315-318.
6. Park SH, Kim CG, Kim JY, et al. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int. 2008;28:475-477.
7. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein- Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317-1321.
8. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein- Barr virus infection. Am J Hematol. 2007;82: 1106-1109.